METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo drug shows promise for fatty liver in diabetes patients
Disease control ENROLLING_BY_INVITATIONThis study compares a combination diabetes drug (iGlarLixi) to insulin alone to see which better reduces liver fat in people with type 2 diabetes and fatty liver disease. About 36 participants will take the assigned treatment for 12 weeks. The goal is to find a better way to mana…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: PHASE4 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated May 17, 2026 12:57 UTC
-
Can a culturally tailored weight loss program help hispanic patients with fatty liver?
Disease control OngoingThis study looks at whether a weight loss program called "Paso a Paso" is practical for Mexican and Central American adults with fatty liver disease and overweight. Researchers will track attendance, weight loss, liver health, and diet changes in 50 participants. The goal is to s…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: NA • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 17, 2026 12:54 UTC
-
New drug shows promise against fatty liver cirrhosis
Disease control OngoingThis study tests an experimental drug called efinopegdutide in 80 adults with liver cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease. The goal is to see if the drug can lower liver fat, inflammation, and scarring compared …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
New ultrasound could spot fatty liver in kids without a needle
Diagnosis OngoingThis study checks if a quick ultrasound called Velacur can accurately detect fatty liver disease (MASLD) in children aged 2 to 20. About 200 kids with suspected liver issues will get the ultrasound, and results will be compared to MRI or liver biopsy. The goal is to find a faster…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: NA • Sponsor: Emory University • Aim: Diagnosis
Last updated May 15, 2026 11:53 UTC
-
New MRI scan could replace needle biopsy for liver scarring
Diagnosis ENROLLING_BY_INVITATIONThis study aims to see if a special MRI scan can accurately measure liver scarring in people with MASH, a type of fatty liver disease. Researchers will compare the MRI results with standard tests like ultrasound and blood work. The goal is to find a noninvasive way to diagnose li…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Diagnosis
Last updated May 12, 2026 13:42 UTC
-
App-Based diet program aims to slim down fatty liver in HIV patients
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a mobile app-based nutritional program helps people living with HIV and fatty liver disease lose at least 5% of their body weight. Participants are randomly assigned to either the app program or standard healthy lifestyle advice. The goal is to improve li…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: NA • Sponsor: Hospital Universitari de Bellvitge • Aim: Symptom relief
Last updated May 13, 2026 15:58 UTC
-
Major study aims to end painful liver biopsies for thousands
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 1,689 adults with fatty liver disease (MASLD) to see if non-invasive tests like MRI and Fibroscan can accurately track disease progression and treatment response. The goal is to reduce the need for liver biopsies in future research and routine care. Participant…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Sponsor: HRI-MAIL-NIT • Aim: Knowledge-focused
Last updated May 14, 2026 12:05 UTC